{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T05:21:48Z","timestamp":1794547308628,"version":"4.9.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2024,10,27]],"date-time":"2024-10-27T00:00:00Z","timestamp":1729987200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,10,27]],"date-time":"2024-10-27T00:00:00Z","timestamp":1729987200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1007\/s40262-024-01426-8","type":"journal-article","created":{"date-parts":[[2024,10,28]],"date-time":"2024-10-28T09:00:07Z","timestamp":1730106007000},"page":"1585-1595","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Changes in Plasma Clearance of CYP450 Probe Drugs May Not be Specific for Altered In Vivo Enzyme Activity Under (Patho)Physiological Conditions: How to Interpret Findings of Probe Cocktail Studies"],"prefix":"10.1007","volume":"63","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9719-6051","authenticated-orcid":false,"given":"Laura M.","family":"de Jong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9904-131X","authenticated-orcid":false,"given":"Marinda","family":"van de Kreeke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariam","family":"Ahmadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3965-5552","authenticated-orcid":false,"given":"Jesse J.","family":"Swen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9893-4415","authenticated-orcid":false,"given":"Catherijne A. J.","family":"Knibbe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1664-7314","authenticated-orcid":false,"given":"J. G. Coen","family":"van Hasselt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5508-8615","authenticated-orcid":false,"given":"Martijn L.","family":"Manson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6006-1567","authenticated-orcid":false,"given":"Elke H. J.","family":"Krekels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,27]]},"reference":[{"key":"1426_CR1","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/0165-6147(90)90245-4","volume":"11","author":"DD Breimer","year":"1990","unstructured":"Breimer DD, Schellens JH. A \u201ccocktail\u201d strategy to assess in vivo oxidative drug metabolism in humans. Trends Pharmacol Sci. 1990;11:223\u20135. https:\/\/doi.org\/10.1016\/0165-6147(90)90245-4.","journal-title":"Trends Pharmacol Sci"},{"key":"1426_CR2","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/sj.clpt.6100050","volume":"81","author":"U Fuhr","year":"2007","unstructured":"Fuhr U, Jetter A, Kirchheiner J. Appropriate phenotyping procedures for drug metabolizing enzymes and transporters in humans and their simultaneous use in the \u201ccocktail\u201d approach. Clin Pharmacol Ther. 2007;81:270\u201383. https:\/\/doi.org\/10.1038\/sj.clpt.6100050.","journal-title":"Clin Pharmacol Ther"},{"key":"1426_CR3","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.2174\/1389201017666160926150117","volume":"17","author":"F de Andr\u00e9s","year":"2016","unstructured":"de Andr\u00e9s F, LLerena A. Simultaneous determination of cytochrome P450 oxidation capacity in humans: a review on the phenotyping cocktail approach. Curr Pharm Biotechnol. 2016;17:1159\u201380. https:\/\/doi.org\/10.2174\/1389201017666160926150117.","journal-title":"Curr Pharm Biotechnol"},{"key":"1426_CR4","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1002\/cpt.2146","volume":"109","author":"C Lenoir","year":"2021","unstructured":"Lenoir C, Daali Y, Rollason V, Curtin F, Gloor Y, Bosilkovska M, et al. Impact of acute inflammation on cytochromes P450 activity assessed by the Geneva Cocktail. Clin Pharmacol Ther. 2021;109:1668\u201376. https:\/\/doi.org\/10.1002\/cpt.2146.","journal-title":"Clin Pharmacol Ther"},{"key":"1426_CR5","doi-asserted-by":"publisher","DOI":"10.3390\/jpm13071042","author":"H Ghasim","year":"2023","unstructured":"Ghasim H, Rouini M, Safari S, Larti F, Khoshayand M, Gholami K, et al. Impact of obesity and bariatric surgery on metabolic enzymes and P-glycoprotein activity using the Geneva Cocktail approach. J Pers Med. 2023. https:\/\/doi.org\/10.3390\/jpm13071042.","journal-title":"J Pers Med"},{"key":"1426_CR6","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/j.ajog.2004.08.030","volume":"192","author":"TS Tracy","year":"2005","unstructured":"Tracy TS, Venkataramanan R, Glover DD, Caritis SN. Temporal changes in drug metabolism (CYP1A2, CYP2D6 and CYP3A Activity) during pregnancy. Am J Obstet Gynecol. 2005;192:633\u20139. https:\/\/doi.org\/10.1016\/j.ajog.2004.08.030.","journal-title":"Am J Obstet Gynecol"},{"key":"1426_CR7","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1080\/10837450902891360","volume":"41","author":"P Espi\u00e9","year":"2009","unstructured":"Espi\u00e9 P, Tytgat D, Sargentini-Maier M-L, Poggesi I, Watelet J-B. Physiologically based pharmacokinetics (PBPK). Drug Metab Rev. 2009;41:391\u2013407. https:\/\/doi.org\/10.1080\/10837450902891360.","journal-title":"Drug Metab Rev"},{"key":"1426_CR8","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1002\/jcph.1093","volume":"58","author":"DE Coutant","year":"2018","unstructured":"Coutant DE, Hall SD. Disease-drug interactions in inflammatory states via effects on CYP-mediated drug clearance. J Clin Pharmacol. 2018;58:849\u201363. https:\/\/doi.org\/10.1002\/jcph.1093.","journal-title":"J Clin Pharmacol"},{"key":"1426_CR9","doi-asserted-by":"publisher","DOI":"10.1042\/BSR20200817","volume":"40","author":"DK Djakpo","year":"2020","unstructured":"Djakpo DK, Wang Z, Zhang R, Chen X, Chen P, Antoine MMLK. Blood routine test in mild and common 2019 coronavirus (COVID-19) patients. Biosci Rep. 2020;40: BSR20200817. https:\/\/doi.org\/10.1042\/BSR20200817.","journal-title":"Biosci Rep"},{"key":"1426_CR10","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1590\/S0104-42302012000600015","volume":"58","author":"RC Santos","year":"2012","unstructured":"Santos RC, Figueiredo VN, Martins LC, Moraes CH, Quinaglia T, Boer-Martins L, et al. Infliximab reduces cardiac output in rheumatoid arthritis patients without heart failure. Rev Assoc M\u00e9dica Bras. 2012;58:698\u2013702. https:\/\/doi.org\/10.1590\/S0104-42302012000600015.","journal-title":"Rev Assoc M\u00e9dica Bras"},{"key":"1426_CR11","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/BF01106706","volume":"14","author":"MS Roberts","year":"1986","unstructured":"Roberts MS, Rowland M. A dispersion model of hepatic elimination: 1. Formulation of the model and bolus considerations. J Pharmacokinet Biopharm. 1986;14:227\u201360. https:\/\/doi.org\/10.1007\/BF01106706.","journal-title":"J Pharmacokinet Biopharm"},{"key":"1426_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1023\/A:1022531403741","volume":"29","author":"D Ridgway","year":"2003","unstructured":"Ridgway D, Tuszynski JA, Tam YK. Reassessing models of hepatic extraction. J Biol Phys. 2003;29:1\u201321. https:\/\/doi.org\/10.1023\/A:1022531403741.","journal-title":"J Biol Phys"},{"key":"1426_CR13","first-page":"1316","volume":"29","author":"Y Naritomi","year":"2001","unstructured":"Naritomi Y, Terashita S, Kimura S, Suzuki A, Kagayama A, Sugiyama Y. Prediction of human hepatic clearance from in vivo animal experiments and in vitro metabolic studies with liver microsomes from animals and humans. Drug Metab Dispos. 2001;29:1316\u201324.","journal-title":"Drug Metab Dispos"},{"key":"1426_CR14","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1164\/rccm.201510-2114OC","volume":"194","author":"NJ Vet","year":"2016","unstructured":"Vet NJ, Brussee JM, De Hoog M, Mooij MG, Verlaat CWM, Jerchel IS, et al. Inflammation and organ failure severely affect midazolam clearance in critically ill children. Am J Respir Crit Care Med. 2016;194:58\u201366. https:\/\/doi.org\/10.1164\/rccm.201510-2114OC.","journal-title":"Am J Respir Crit Care Med"},{"key":"1426_CR15","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1124\/dmd.115.067595","volume":"44","author":"F Salem","year":"2016","unstructured":"Salem F, Abduljalil K, Kamiyama Y, Rostami-Hodjegan A. Considering age variation when coining drugs as high versus low hepatic extraction ratio. Drug Metab Dispos. 2016;44:1099\u2013102. https:\/\/doi.org\/10.1124\/dmd.115.067595.","journal-title":"Drug Metab Dispos"},{"key":"1426_CR16","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1111\/cts.13142","volume":"15","author":"KE Kvitne","year":"2022","unstructured":"Kvitne KE, Robertsen I, Skovlund E, Christensen H, Krogstad V, Wegler C, et al. Short- and long-term effects of body weight loss following calorie restriction and gastric bypass on CYP3A-activity\u2014a non-randomized three-armed controlled trial. Clin Transl Sci. 2022;15:221\u201333. https:\/\/doi.org\/10.1111\/cts.13142.","journal-title":"Clin Transl Sci"},{"key":"1426_CR17","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/s40005-013-0073-4","volume":"43","author":"S-J Cho","year":"2013","unstructured":"Cho S-J, Yoon I-S, Kim D-D. Obesity-related physiological changes and their pharmacokinetic consequences. J Pharm Investig. 2013;43:161\u20139. https:\/\/doi.org\/10.1007\/s40005-013-0073-4.","journal-title":"J Pharm Investig"},{"key":"1426_CR18","first-page":"1","volume":"40","author":"JM Kremer","year":"1988","unstructured":"Kremer JM, Wilting J, Janssen LH. Drug binding to human alpha-1-acid glycoprotein in health and disease. Pharmacol Rev. 1988;40:1\u201347.","journal-title":"Pharmacol Rev"},{"key":"1426_CR19","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1002\/cpt.2698","volume":"112","author":"EC Le Carpentier","year":"2022","unstructured":"Le Carpentier EC, Canet E, Masson D, Martin M, Deslandes G, Gaultier A, et al. Impact of inflammation on midazolam metabolism in severe COVID-19 patients. Clin Pharmacol Ther. 2022;112:1033\u20139. https:\/\/doi.org\/10.1002\/cpt.2698.","journal-title":"Clin Pharmacol Ther"},{"key":"1426_CR20","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1124\/dmd.117.077644","volume":"45","author":"H Li","year":"2017","unstructured":"Li H, Canet MJ, Clarke JD, Billheimer D, Xanthakos SA, Lavine JE, et al. Pediatric cytochrome P450 activity alterations in nonalcoholic steatohepatitis. Drug Metab Dispos Biol Fate Chem. 2017;45:1317\u201325. https:\/\/doi.org\/10.1124\/dmd.117.077644.","journal-title":"Drug Metab Dispos Biol Fate Chem"},{"key":"1426_CR21","doi-asserted-by":"publisher","first-page":"4121","DOI":"10.1111\/bcp.15349","volume":"88","author":"KE Kvitne","year":"2022","unstructured":"Kvitne KE, Krogstad V, Wegler C, Johnson LK, Kringen MK, Hovd MH, et al. Short- and long-term effects of body weight, calorie restriction and gastric bypass on CYP1A2, CYP2C19 and CYP2C9 activity. Br J Clin Pharmacol. 2022;88:4121\u201333. https:\/\/doi.org\/10.1111\/bcp.15349.","journal-title":"Br J Clin Pharmacol"},{"key":"1426_CR22","doi-asserted-by":"publisher","first-page":"2685","DOI":"10.1111\/cts.13394","volume":"15","author":"KE Kvitne","year":"2022","unstructured":"Kvitne KE, \u00c5sberg A, Johnson LK, Wegler C, Hertel JK, Artursson P, et al. Impact of type 2 diabetes on in vivo activities and protein expressions of cytochrome P450 in patients with obesity. Clin Transl Sci. 2022;15:2685\u201396. https:\/\/doi.org\/10.1111\/cts.13394.","journal-title":"Clin Transl Sci"},{"key":"1426_CR23","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1002\/cpt.2412","volume":"110","author":"C Lenoir","year":"2021","unstructured":"Lenoir C, Terrier J, Gloor Y, Curtin F, Rollason V, Desmeules JA, et al. Impact of SARS-CoV-2 infection (COVID-19) on cytochromes P450 activity assessed by the Geneva Cocktail. Clin Pharmacol Ther. 2021;110:1358\u201367. https:\/\/doi.org\/10.1002\/cpt.2412.","journal-title":"Clin Pharmacol Ther"},{"key":"1426_CR24","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.733935","volume":"12","author":"C Lenoir","year":"2021","unstructured":"Lenoir C, Rollason V, Desmeules JA, Samer CF. Influence of inflammation on cytochromes P450 activity in adults: a systematic review of the literature. Front Pharmacol. 2021;12: 733935. https:\/\/doi.org\/10.3389\/fphar.2021.733935.","journal-title":"Front Pharmacol"},{"key":"1426_CR25","unstructured":"Zwangerschap\/Lactatie n.d. https:\/\/www.farmacotherapeutischkompas.nl\/farmacologie\/zwangerschap-lactatie. Accessed 15 Jan 2024."},{"key":"1426_CR26","volume-title":"Guideline on the investigation of drug interactions","author":"European Medicines Agency","year":"2013","unstructured":"European Medicines Agency. Guideline on the investigation of drug interactions. Amsterdam: European Medicines Agency; 2013."},{"key":"1426_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2020.107627","volume":"215","author":"F Stanke-Labesque","year":"2020","unstructured":"Stanke-Labesque F, Gautier-Veyret E, Chhun S, Guilhaumou R. Inflammation is a major regulator of drug metabolizing enzymes and transporters: consequences for the personalization of drug treatment. Pharmacol Ther. 2020;215: 107627. https:\/\/doi.org\/10.1016\/j.pharmthera.2020.107627.","journal-title":"Pharmacol Ther"},{"key":"1426_CR28","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1038\/clpt.2013.79","volume":"94","author":"KK Machavaram","year":"2013","unstructured":"Machavaram KK, Almond LM, Rostami-Hodjegan A, Gardner I, Jamei M, Tay S, et al. A physiologically based pharmacokinetic modeling approach to predict disease-drug interactions: suppression of CYP3A by IL-6. Clin Pharmacol Ther. 2013;94:260\u20138. https:\/\/doi.org\/10.1038\/clpt.2013.79.","journal-title":"Clin Pharmacol Ther"},{"key":"1426_CR29","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/s11095-021-03019-7","volume":"38","author":"F Simon","year":"2021","unstructured":"Simon F, Gautier-Veyret E, Truffot A, Chenel M, Payen L, Stanke-Labesque F, et al. Modeling approach to predict the impact of inflammation on the pharmacokinetics of CYP2C19 and CYP3A4 substrates. Pharm Res. 2021;38:415\u201328. https:\/\/doi.org\/10.1007\/s11095-021-03019-7.","journal-title":"Pharm Res"},{"key":"1426_CR30","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s00228-004-0754-z","volume":"60","author":"A Jetter","year":"2004","unstructured":"Jetter A, Kinzig-Schippers M, Skott A, Lazar A, Tomalik-Scharte D, Kirchheiner J, et al. Cytochrome P450 2C9 phenotyping using low-dose tolbutamide. Eur J Clin Pharmacol. 2004;60:165\u201371. https:\/\/doi.org\/10.1007\/s00228-004-0754-z.","journal-title":"Eur J Clin Pharmacol"},{"key":"1426_CR31","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1097\/00008571-199604000-00003","volume":"6","author":"U Fuhr","year":"1996","unstructured":"Fuhr U, Rost KL, Engelhardt R, Sachs M, Liermann D, Belloc C, et al. Evaluation of caffeine as a test drug for CYP1A2, NAT2 and CYP2E1 phenotyping in man by in vivo versus in vitro correlations. Pharmacogenetics. 1996;6:159\u201376. https:\/\/doi.org\/10.1097\/00008571-199604000-00003.","journal-title":"Pharmacogenetics"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-024-01426-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-024-01426-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-024-01426-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,18]],"date-time":"2024-11-18T16:06:45Z","timestamp":1731946005000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-024-01426-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,27]]},"references-count":31,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["1426"],"URL":"https:\/\/doi.org\/10.1007\/s40262-024-01426-8","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,27]]},"assertion":[{"value":"10 September 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No sources of funding were received for this work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Laura M. de Jong, Marinda van de Kreeke, Mariam Ahmadi, Jesse J. Swen, Catherijne A.J. Knibbe, J.G. Coen van Hasselt, Martijn L. Manson, and Elke H.J. Krekels have declared no conflicts of interest\/competing interests for this work.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Available upon request.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Available upon request.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"LMJ, MA, MLM, and EHJK designed the research; LMJ, MK, MA, and EHJK performed the research. All authors contributed to interpreting the results, and all authors wrote the manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}